Spastazoline
Based on 4 publication(s) in Google Scholar
Spastazoline is a selective spastin (a microtubule-severing AAA protein) inhibitor, with an IC50 of 99 nM for Human spastin. Spastazoline can be used for cell division- and intracellular vesicle transport-related research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.50%
- CAS No.: 2351882-11-4
- Formule: C20H30N8
- Masse moléculaire:382.51
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Anti-Aging Compound Library
HY-L034
-
Cytoskeleton Compound Library
HY-L060
-
Anti-Lung Cancer Compound Library
HY-L075
-
Targeted Diversity Library
HY-L099
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Heterocyclic Compound Library
HY-L138
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Efficiency Gene Editing Compound Library
HY-L244
Publications Citing Use of MedChemExpress (MCE) Spastazoline
More
Activité biologique
IC50: 99 nM (Human spastin)[1]
Spastazoline (10 μM; 4.5 h) affects division of HeLa cells by increasing the number of HeLa cells with intercellular bridges[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2351882-11-4
-
Appearance Solid
-
Masse moléculaire 382.51
-
Formule C20H30N8
-
Color Off-white to gray
-
SMILES
CC(C)(C)C1=CC(NC2=NC(N3CCN[C@H](C(C)C)C3)=NC4=C2C=CN4)=NN1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Eur J Neurol
New cellular imaging-based method to distinguish SPG4 subtype of Hereditary Spastic Paraplegia. [Abstract]2023 Jun;30(6):1734-1744. PMID: 36815539 -
Life Sci Alliance
Reticulon-1 synthesis controls outgrowth and microtubule dynamics in injured cortical axons. [Abstract]2026 Jan 16;9(4):e202503571. PMID: 41545196 -
-
Solvant et solubilité
DMSO : 100 mg/mL (261.43 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5.25 mg/mL (13.73 mM); Clear solution
This protocol yields a clear solution of ≥ 5.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (52.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5.25 mg/mL (13.73 mM); Clear solution
This protocol yields a clear solution of ≥ 5.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (52.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6143 mL | 13.0716 mL | 26.1431 mL | 65.3578 mL |
| 5 mM | 0.5229 mL | 2.6143 mL | 5.2286 mL | 13.0716 mL | |
| 10 mM | 0.2614 mL | 1.3072 mL | 2.6143 mL | 6.5358 mL | |
| 15 mM | 0.1743 mL | 0.8714 mL | 1.7429 mL | 4.3572 mL | |
| 20 mM | 0.1307 mL | 0.6536 mL | 1.3072 mL | 3.2679 mL | |
| 25 mM | 0.1046 mL | 0.5229 mL | 1.0457 mL | 2.6143 mL | |
| 30 mM | 0.0871 mL | 0.4357 mL | 0.8714 mL | 2.1786 mL | |
| 40 mM | 0.0654 mL | 0.3268 mL | 0.6536 mL | 1.6339 mL | |
| 50 mM | 0.0523 mL | 0.2614 mL | 0.5229 mL | 1.3072 mL | |
| 60 mM | 0.0436 mL | 0.2179 mL | 0.4357 mL | 1.0893 mL | |
| 80 mM | 0.0327 mL | 0.1634 mL | 0.3268 mL | 0.8170 mL | |
| 100 mM | 0.0261 mL | 0.1307 mL | 0.2614 mL | 0.6536 mL |
Spastazoline Related Classifications
HY-111548 Related Classifications
Powered by Bioz